Key facts
- Atonco’s last known valuation is $24.6M (Oct 2025).
- It has raised $10.0M; the latest was Later Stage VC ($4.7M) in Oct 2025.
- Notable investors include Atlanpole, Remora Biotech.
- Status: Privately Held (backing).
Investors
2- ·The complete investor list — 2 names
- ·Watchlist + deal alerts for Atonco
- ·The full record, as it builds
Funding rounds
No funding rounds for Atonco are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Atonco
Developer of targeted radiopharmaceutical therapy intended for cancer treatment. The company's platform utilizes a short half-life alpha-particle-emitting radionuclide coupled with proprietary radiolabeling technology and an antibody, enabling the oncology market to address unmet clinical needs through precise tumor targeting, effective elimination of residual disease, and minimized damage to surrounding healthy tissue due to the short path length of alpha emissions.
- Sector
- Healthcare
- HQ
- Saint-Herblain, France
- Founded
- 2019
- Employees
- 9
- Website
- atonco-pharma.com/
- Ownership
- Privately Held (backing)
Atonco doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Atonco shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Atonco in its N-PORT filings yet. We sweep new filings monthly.